Influence of pregnancy on outcomes of inflammatory bowel disease and treatment discontinuation

Table 3 Clinical outcomes and demographic data of patients with Crohn’s disease who continued and discontinued therapy, median (interquartile range)/n (%)

	Continued treatment (n = 16)	Discontinued treatment (n = 4)	P value
Age at onset of disease, years	19 (11-27)	22 (18-24)	0.704
Total disease duration, months	112.2 (20.27-328.73)	154.83 (74.33-261.17)	0.508
Smoking			0.162
None	14 (87.5)	2 (50)
Existing/current	2 (12.5)	2 (50)
BMI (kg/m2)	20.2 (16.02-26.73)	21.72 (20.81-23.44)	0.300
Family history of IBD	2 (12.5)	1 (25)	0.509
Appendectomy	2 (12.5)	1 (25)	0.509
CD disease location			0.535
Ileal (L1)	6 (37.5)	2 (50)
Colonic (L2)	4 (25)
Ileo-colonic (L3)	6 (37.5)	2 (50)
CD perianal involvement	6 (37.5)	2 (50)	1
CD disease behavior			0.189
Inflammatory disease (B1)	10 (62.5)	2 (50)
Stenosing (B2)	2 (12.5)	2 (50)
Penetrating (B3)	4 (25)
CRP (mg/L)	15.4 (0.8-166)	17.7 (0.5-60)	0.741
HB (g/dL)	10.45 (8.4-15)	12.8 (10.5-14.4)	0.065
Albumin (g/dL)	4.05 (2.9-4.9)	4.4 (3.8-4.6)	0.419
CDAI	334.5 (216-514)	302 (202-456)	0.705
Disease activation	9 (56.3)	1 (25)	0.582
Current treatment	12 (75)	4 (100)	0.538
Mesalazine		3 (75)	0.004a
Thiopurine	1 (6.3)		1
Biologics
Adalimumab	4 (25)		0.538
Infliximab	6 (37.5)	1 (25)	1
Vedolizumab	1 (6.3)		1
History of abortion	5 (31.3)	1 (25)	1

^aP < 0.01.

BMI: Body mass index; IBD: Inflammatory bowel disease; CD: Crohn’s disease; CRP: C-reactive protein; HB: Hemoglobin; CDAI: Crohn’s Disease Activity Index.